Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auto-hMSCs vs Allo-hMSCs in Chronic Ischemic Left Ventricular Dysfunction
NCT01087996Phase 2Completed
- Sponsor
- University of Miami
- Start
- Mar 2010
- Primary completion
- Apr 2011
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of human mesenchymal stem cells and allogeneic bone marrow-derived human mesenchymal stem cells in ischemic cardiomyopathy (ICM) (2 arms), sponsored by University of Miami. Primary endpoint: Treatment-Emergent Serious Adverse Events at 1 month. Started Mar 2010; status: completed.
02
Drugs
human mesenchymal stem cellsallogeneic bone marrow-derived human mesenchymal stem cells
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT01087996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01087996.